liberDi

liberDi is developing a portable, automatic system that significantly reduces the burden of performing peritoneal dialysis (PD).

The market seeks an effective, easy-to-use dialysis solution for improved treatment benefits and reduced health care costs.

liberDi’s Novel Solution

The lightweight liberDi system gives patients with end-stage renal disease (ESRD) the opportunity to perform PD anywhere or anytime – home, office, vacation – for increased freedom of movement and greatly improved quality of life.

The automatic system offers easy setup and maintenance and is expected to reduce treatment time and infection rates. liberDi’s system provides the opportunity for more patients to use and benefit from PD treatment.

The results: improved patient satisfaction, improved treatment outcomes, and reduced health care costs.

The Team & Advisory Board

liberDi CEO Hezkiah Tsoory

liberDi CEO Hezkiah Tsoory

  • Hezkiah Tsoory, Founder, and CEO: Extensive experience in international business, operations, and R&D; former VP Business Development, Nanocell; COO, D Medical Industries (TASE, Nasdaq: DMED);, COO, MCS (TASE: MDCL); VP Operations, Mentorwave; VP Manufacturing, Power Paper
  • Victor Frajewicki, M.D., Medical Advisor: Over 20 years’ experience as a specialist in nephrology and hypertension; Head, Department of Nephrology and Hypertension, Carmel Medical Center, Haifa, Israel; VP, Israeli Society of Nephrology and Hypertension
  • Daniel Kushnir, M.D., Medical Advisor: Head of Dialysis Unit, Carmel Medical Center, Haifa, Israel; specialist in nephrology and internal medicine; 20 years’ experience in nephrology
  • Professor Avry Chagnac, M.D., Medical Advisor: Specialist in internal medicine and nephrology; extensive clinical and research experience in nephrology in general, and in peritoneal dialysis, in particular; Head, Institute of Nephrology, Rabin Medical Center, Petah Tikva, Israel

Status

Founded: December 2016 (incubated)
Stage: Technology development
Investors: The Trendlines Group, Technion-Israel Institute of Technology

Background & Market

ESRD is characterized by a drop in kidney function below 10% of normal. Treatment involves kidney transplant or dialysis.

Currently, dialysis is performed at a dialysis center by means of an artificial kidney (hemodialyzer) in four-hour sessions, three times per week. In some cases, dialysis can be performed at home on a daily basis using the patient’s peritoneal membrane (of the abdomen) to act as a blood filter.

At-home PD offers numerous benefits. For patients, it eliminates the need to travel to dialysis centers and provides flexibility to maintain everyday work and activities. For the health care system, PD presents a more affordable treatment modality. Unfortunately, current PD systems are bulky and suffer from a particularly cumbersome setup and complicated regimen. They may also increase the risk of peritonitis.

Worldwide, 3.3 million people suffer from ESRD. This number continues to grow due to an aging population, and rise of diabetes, hypertension, and obesity. According to Markets and Markets, the global dialysis market was $61 billion in 2013, with a CAGR of 6.2% over the next five years.

smiling family
liberDi is developing a portable, automatic system for peritoneal dialysis.

Contact

Hezkiah Tsoory, CEO & Founder
+972.54.620.0722
hezkiah@liberdi.com
www.liberdi.com

liberDi portfolio card

Font Resize
Contrast